Results 121 to 130 of about 24,414 (214)
Vascular Health and Risk Management, 2017 Alberico Luigi Catapano,1,2 Angela Pirillo,1,2 Giuseppe Danilo Norata1,3,4 1Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 2IRCCS Multimedica Hospital, Sesto San Giovanni, 3Center for the Study of ...
Catapano AL, Pirillo A, Norata GD
doaj
Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9 [PDF]
The American Journal of Pathology, 2020 Chiara Macchi +13 more
openaire +1 more source
Beyond lipids: Systemic effects of lipoprotein apheresis
Transfusion, Volume 66, Issue 3, Page 590-598, March 2026.
Menatalla Nadim, Yamac Akgun
wiley +1 more source
[Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2015 Hypercholesterolemia is a major risk factor for atherosclerosis. Low-density lipoprotein cholesterol (LDL-C) lowering drugs reduce cardiovascular morbidity and mortality. However, many individuals treated with statins do not achieve their target levels of LDL-C.
Ahmet, Avci +2 more
openaire +1 more source
Therapeutic Strategies for Hypercholesterolemia
healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins SuissesA high cholesterol level in the blood is associated with an increased risk of atherosclerosis and its related conditions such as heart attack and stroke.
Georg Noll +3 more
doaj +1 more source
Proprotein convertase subtilisin/kexin type 9 (PCSK9) [PDF]
Science-Business eXchange, 2012 openaire +1 more source
Proprotein convertase subtilisin kexin type 9 (PCSK9) [PDF]
Science-Business eXchange, 2009 openaire +1 more source
Transforming growth factor beta reduces proprotein convertase subtilisin/kexin type 9 in the supernatant of hepatic stellate cells. [PDF]
World J HepatolBundschuh J +4 more
europepmc +1 more source